New Zealand markets closed

Plus Therapeutics, Inc. (PSTV)

NasdaqCM - NasdaqCM Delayed price. Currency in USD
Add to watchlist
1.8050-0.0650 (-3.48%)
At close: 04:00PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close1.8700
Open1.8100
Bid1.8800 x 100
Ask1.8800 x 100
Day's range1.7600 - 1.8450
52-week range0.9700 - 5.1000
Volume41,260
Avg. volume33,047
Market cap7.86M
Beta (5Y monthly)0.60
PE ratio (TTM)N/A
EPS (TTM)-4.2400
Earnings date18 Apr 2024 - 22 Apr 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est28.20
  • GlobeNewswire

    Plus Therapeutics to Present at the National Comprehensive Cancer Network Annual Conference

    AUSTIN, Texas, March 27, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announced that it will present a poster at the National Comprehensive Cancer Network (NCCN) 2024 Annual Conference, which will be held April 5-7, 2024, in Orlando, Florida. NCCN 2024 Annual Conference – Orlando World Center Marriott

  • GlobeNewswire

    Plus Therapeutics Announces Validation & Clinical Implementation of CSF-01 Leptomeningeal Cancer Cell Diagnostic

    Plus’ CSF-01 cancer cell enumeration test is a sensitive and specific diagnostic test for the presence of adenocarcinoma and melanoma cancer cells in the leptomeninges CSF-01 testing is used as an exploratory endpoint in the ReSPECT-LM trials Controlled clinical trial data evaluating the utility of CSF-01 in clinical decision-making is anticipated to be released in Q2/Q3 2024 AUSTIN, Texas, March 25, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stag

  • GlobeNewswire

    Plus Therapeutics Completes Dosing in Cohort 5 of ReSPECT-LM Phase 1 Trial of Rhenium (186Re) Obisbemeda in Leptomeningeal Metastases

    A total of 18 patients have been dosed in the trial to date Company anticipates moving into Cohort 6 in Q2 2024 following standard safety review AUSTIN, Texas, March 11, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announced it has completed dosing in Cohort 5 of the ReSPECT-LM Phase 1 dose escalation